Stock RVV REVIVE THERAPEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Revive Therapeutics Ltd.

Equities

RVV

CA7615161030

Delayed Canadian Securities Exchange
Other stock markets
 09:56:15 2024-05-03 am EDT 		5-day change 1st Jan Change
0.025 CAD 0.00% Intraday chart for Revive Therapeutics Ltd. -16.67% -16.67%
Apr. 23 FDA Grants Revive Therapeutics Type C Meeting Request For Bucillamine Study to Treat Long COVID MT
Apr. 23 Revive Therapeutics Brief: Announcing Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
GL
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
GL
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
GL
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
AQ
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
GL
Revive Therapeutics : Document
PU
Revive Therapeutics : Document
PU
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
GL
Revive Therapeutics Provides Corporate Update
GL
Revive Therapeutics Provides Corporate Update
AQ
Revive Therapeutics : Document
PU
Revive Therapeutics : Document
PU
Revive Therapeutics : Document
PU
Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110
GL
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
GL
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
AQ
Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500
GL
Revive Therapeutics Ltd. Announces Offering of Up to $3 Million
GL
Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada
GL
Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RVV Stock
  4. News Revive Therapeutics Ltd.
  5. Press Releases